CHRONIC KIDNEY DISEASE DRUGS MARKET ANALYSIS

Chronic Kidney Disease Drugs Market, By Drug Class (ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), B-Blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, Others), By Route of Administration (Oral and Parentral), By Indication (Diabetic Nephropathy, Glomerulonephritis, Hypertensive Nephropathy, Polycystic Kidney Disease, Other Indications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies , Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Feb 2025
Code : CMI1713
Pages :206
Formats :
Excel and PDF
Industry : Pharmaceutical

Chronic Kidney Disease Drugs Market Size and Trends

Global chronic kidney disease drugs market is estimated to be valued at USD 15.92 Billion in 2025 and is expected to reach USD 23.02 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.4% from 2025 to 2032. Increasing geriatric population suffering from chronic conditions such as diabetes and hypertension, rising awareness about early diagnosis, and growing demand for drugs to slow the progression of CKD can drive the market growth.

Chronic Kidney Disease Drugs Market Key Factors

To learn more about this report, Request sample copy

Market Driver - Increasing prevalence of diabetes and hypertension

Rising prevalence of diabetes and hypertension across major regions of the world can drive the chronic kidney disease drugs market growth. Diabetes and hypertension are among the leading causes of chronic kidney disease as these can damage the kidneys over a prolonged period of time, if not managed properly. According to studies, almost 40% of patients with diabetes and 30% of those with hypertension will eventually develop some form of chronic kidney disease. With diabetes rates rising due to growing obesity, sedentary lifestyles and aging populations, there has been corresponding increase in chronic kidney disease cases linked to diabetes. Statistics showed that countries with high diabetes prevalence like the U.S., China, India, Brazil, Mexico, and others have witnessed fastest growth in chronic kidney disease cases attributed to uncontrolled diabetes. Even regions like the Middle East and Africa that already had a high burden of diabetes and hypertension witnessed a surge in end-stage renal disease. This compels healthcare systems to spend more resources on kidney disease treatment and dialysis, placing immense pressure. With no immediately foreseeable decline in the incidence of diabetes and hypertension globally, there will be rise in prevalence of chronic kidney disease caused by these conditions. This growing patient pool suffering from kidney ailments can boost demand for chronic kidney disease drugs for long-term therapy and management.